Spruce Biosciences, Inc.
SPRBAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 5, 2026 | B.Riley Financial | Madison El-Saadi | $160.00(+250%) | $45.71 | StreetInsider |
| Sep 17, 2026 | Lake Street | $149.00(+175%) | $54.16 | TheFly | |
| Aug 17, 2026 | Guggenheim | $104.00(+98%) | $52.64 | TheFly | |
| Jun 16, 2026 | Guggenheim | Debjit Chattopadhyay | $123.00(+146%) | $49.91 | TheFly |
| Jun 1, 2026 | H.C. Wainwright | $150.00(+193%) | $51.27 | TheFly | |
| Apr 27, 2026 | Craig-Hallum | Albert Lowe | $140.00(+152%) | $55.63 | TheFly |
| Dec 23, 2025 | Oppenheimer | $283.00(+242%) | $82.82 | TheFly | |
| Nov 11, 2025 | JMP Securities | $259.00(+124%) | $115.61 | TheFly | |
| Oct 28, 2025 | JMP Securities | $254.00(+106%) | $123.02 | TheFly | |
| Oct 21, 2025 | Leerink Partners | $160.00(+19%) | $134.00 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citizens | maintain | Market Outperform | Sep 24, 2026 |
| Guggenheim | maintain | Buy | Aug 17, 2026 |
| Citizens | maintain | Market Outperform | Aug 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 1, 2026 |
| Citizens | maintain | Market Outperform | May 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 10, 2026 |
| Citizens | maintain | Market Outperform | Mar 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 19, 2026 |
| Leerink Partners | upgrade | Market Perform →Outperform | Dec 3, 2025 |
| Citizens | maintain | Market Outperform | Nov 11, 2025 |
| JMP Securities | upgrade | Market Perform →Market Outperform | Oct 28, 2025 |
| Leerink Partners | maintain | Market Perform | Oct 21, 2025 |
| RBC Capital | maintain | Sector Perform | Apr 16, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Dec 16, 2024 |
| Guggenheim | maintain | Neutral | Dec 12, 2024 |
| Oppenheimer | downgrade | Outperform →Perform | Dec 11, 2024 |
| JMP Securities | downgrade | Market Outperform →Market Perform | Dec 11, 2024 |
| RBC Capital | maintain | Sector Perform | Dec 11, 2024 |
| RBC Capital | maintain | Sector Perform | Nov 12, 2024 |
| RBC Capital | maintain | Sector Perform | Aug 13, 2024 |
| Oppenheimer | maintain | Outperform | Jun 13, 2024 |
| Guggenheim | downgrade | Buy →Neutral | Mar 14, 2024 |
| RBC Capital | downgrade | Outperform →Sector Perform | Mar 14, 2024 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Mar 14, 2024 |
| Leerink Partners | downgrade | Outperform →Market Perform | Mar 14, 2024 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-6.68 | $-5.79 | — | — |
| May 13, 2026 | $-8.94 | $-7.32 | — | — |
| Mar 9, 2026 | $-9.58 | $-12.87 | — | $500.0K |
| Nov 10, 2025 | $-14.58 | $-15.56 | — | $500.0K |
| Aug 15, 2025 | $-3.50 | $-18.00 | — | $500.0K |
| May 6, 2025 | $-24.00 | $-18.80 | — | $250.0K |
| Apr 15, 2025 | $-42.75 | $-0.24 | $700.0K | $885.0K |
| Nov 11, 2024 | $-15.79 | $-0.27 | $602.0K | $1.5M |
News
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026 at 11:30 a.m. ET in Boston, MA.Interested parties can.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Craig-Hallum Biotech Catalyst Conference on October 22, 2026. An archived copy of the webcast will be available on the events sec.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data from Study 250-902 (NCT03227042), a prospective, multicenter, multinational, noninterventional, longitudinal natural history study designed to characterize disease progression in pediatric participants with severe, non-attenua…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2:00 p.m. ET in New York.Interested parties can access the live webcas…
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disor
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the launch of MPS3BStudy.com, a dedicated online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB). The website enables families and caregivers to learn about, and register their interest in, t.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has completed two pre-BLA meetings with the U.S. Food and Drug Administration (FDA) that support the company's plan to submit a BLA for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanf.
Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disord
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates. “The second quarter was a period of significant execution as we advanced TA-ERT toward our planned BLA submission in the fourth quarter, which.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Cure Sanfilippo Foundation and the National MPS Society have agreed to make a combined $5.5 million strategic investment in Spruce. The proceeds will be used to partially fund TA-ERT EAP, helping to broaden patient access to invest.